The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Open accessAbstract
CDK4/6 inhibitors have emerged as a powerful class of agents with clinical activity in a number of malignancies. Targeting the cell cycle represents a core attack on a defining feature of cancer. However, the mechanisms through which selective CDK4/6 targeted agents act has few parallels in the current pharmaceutical armamentarium against cancer. Notably, CDK4/6 inhibitors act downstream of most mitogenic signaling cascades, which have implications both related to clinical efficacy and resistance. Core knowledge of cell cycle processes has provided insights into mechanisms of intrinsic resistance to CDK4/6 inhibitors; however, the basis of acquired resistance versus durable response is only beginning to emerge. This review focuses on the mechanism of action and biomarkers to direct the precision use of CDK4/6 inhibitors and rationally-developed combination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Self-citationPalbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Senescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Forging a signature of in vivo senescence
Sharpless, N. E., & Sherr, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3960 · Cited by 1,104
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089
Lundberg, A. S., & Weinberg, R. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.753 · Cited by 1,067
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins
Hinds, P. W., Mittnacht, S., Dulic, V., Arnold, A., Reed, S. I., & Weinberg, R. A. (1992) · Cell · doi:10.1016/0092-8674(92)90249-c · Cited by 995
Sherr, C. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89005-2 · Cited by 980
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Diehl, J. A., Zindy, F., & Sherr, C. J. (1997) · Genes & Development · doi:10.1101/gad.11.8.957 · Cited by 746
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
Kumar, A., Coleman, I., Morrissey, C., Zhang, X., True, L. D., Gulati, R., Etzioni, R., Bolouri, H., Montgomery, B., White, T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4053 · Cited by 738
Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700
Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis
Sicinski, P., Donaher, J. L., Geng, Y., Parker, S. B., Gardner, H., Park, M. Y., Robker, R. L., Richards, J. S., McGinnis, L. K., Biggers, J. D., et al. (1996) · Nature · doi:10.1038/384470a0 · Cited by 697
Zhang, H. S., Gavin, M., Dahiya, A., Postigo, A. A., Ma, D., Luo, R. X., Harbour, J. W., & Dean, D. C. (2000) · Cell · doi:10.1016/s0092-8674(00)80625-x · Cited by 658
Ishida, S., Huang, E., Zuzan, H., Spang, R., Leone, G., West, M., & Nevins, J. R. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.14.4684-4699.2001 · Cited by 596
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation.
Xiong, Y., Zhang, H., & Beach, D. (1993) · Genes & Development · doi:10.1101/gad.7.8.1572 · Cited by 507
Coppé, J.-P., Rodier, F., Patil, C. K., Freund, A., Desprez, P.-Y., & Campisi, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.257071 · Cited by 506
Cycling to Cancer with Cyclin D1
Diehl, J. A. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.72 · Cited by 475
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.006 · Cited by 470
Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Sicinski, P., & Dowdy, S. F. (2014) · eLife · doi:10.7554/elife.02872 · Cited by 461
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0300 · Cited by 444
Prall, O. J., Sarcevic, B., Musgrove, E. A., Watts, C. W., & Sutherland, R. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10882 · Cited by 444
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 415
Putting the stress on senescence
Serrano, M., & Blasco, M. A. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00278-7 · Cited by 413
Dickson, M. A., Tap, W. D., Keohan, M. L., D'Angelo, S. P., Gounder, M. M., Antonescu, C. R., Landa, J., Qin, L.-X., Rathbone, D. D., Condy, M. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5476 · Cited by 399
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1675 · Cited by 394
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
Self-citationCyclin E-induced S phase without activation of the pRb/E2F pathway.
Lukas, J., Herzinger, T., Hansen, K., Moroni, M. C., Resnitzky, D., Helin, K., Reed, S. I., & Bartek, J. (1997) · Genes & Development · doi:10.1101/gad.11.11.1479 · Cited by 378
Inhibition of Ras-Induced Proliferation and Cellular Transformation by p16 INK4
Serrano, M., Gómez-Lahoz, E., DePinho, R. A., Beach, D., & Bar-Sagi, D. (1995) · Science · doi:10.1126/science.7809631 · Cited by 373
Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366
Lukas, J., Bartkova, J., Rohde, M., Strauss, M., & Bartek, J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2600 · Cited by 366
Cyclin D1: polymorphism, aberrant splicing and cancer risk
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209371 · Cited by 363
Self-citationOncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358
Emerging roles for E2F: Beyond the G1/S transition and DNA replication
Cam, H., & Dynlacht, B. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00080-1 · Cited by 349
Miller, T. W., Balko, J. M., Fox, E. M., Ghazoui, Z., Dunbier, A., Anderson, H., Dowsett, M., Jiang, A., Smith, R. A., Maira, S.-M., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0101 · Cited by 346
The Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
Differential Regulation of Retinoblastoma Protein Function by Specific Cdk Phosphorylation Sites
Knudsen, E. S., & Wang, J. Y. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.8313 · Cited by 320
Self-citationMichaud, K., Solomon, D. A., Oermann, E., Kim, J.-S., Zhong, W.-Z., Prados, M. D., Ozawa, T., James, C. D., & Waldman, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4559 · Cited by 319
Infante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1248 · Cited by 317
Schiff, R., Massarweh, S. A., Shou, J., & Osborne, C. K. (2003) · PubMed · Cited by 304
Thangavel, C., Dean, J. L., Ertel, A., Knudsen, K. E., Aldaz, C. M., Witkiewicz, A. K., Clarke, R., & Knudsen, E. S. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0262 · Cited by 302
Self-citationExpression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Konecny, G. E., Winterhoff, B., Kolarova, T., Qi, J., Manivong, K., Dering, J., Yang, G., Chalukya, M., Wang, H.-J., Anderson, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2307 · Cited by 302
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299
Musgrove, E. A., Hamilton, J. A., Lee, C. S., Sweeney, K. J., Watts, C. K., & Sutherland, R. L. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.6.3577 · Cited by 297
Induction of cyclin D1 overexpression by activated ras.
Filmus, J., Robles, A. I., Shi, W., Wong, M. J. H., Colombo, L. L., & Conti, C. J. (1994) · PubMed · Cited by 295
Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P., & Knudsen, E. S. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16776 · Cited by 286
Self-citationKnudsen, E. S., & Wang, J. Y. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.10.5771 · Cited by 286
Self-citationFlavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
Sedlacek, H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., et al. (1996) · International Journal of Oncology · doi:10.3892/ijo.9.6.1143 · Cited by 275
Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0098 · Cited by 273
c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry
Prall, O. W. J., Rogan, E. M., Musgrove, E. A., Watts, C. K. W., & Sutherland, R. L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.8.4499 · Cited by 267
Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
Sutherland, R. L., & Musgrove, E. A. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000023591.45568.77 · Cited by 258
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
Molecular pathways: CDK4 inhibitors for cancer therapy
Dickson, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1551 · Cited by 245
Deciphering the retinoblastoma protein phosphorylation code
Rubin, S. M. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.10.007 · Cited by 245
Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21195 · Cited by 226
Self-citationPattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001613107 · Cited by 223
Lifetime Risk of Melanoma in CDKN2A Mutation Carriers in a Population-Based Sample
Begg, C. B., Orlow, I., Hummer, A. J., Armstrong, B. K., Kricker, A., Marrett, L. D., Millikan, R. C., Gruber, S. B., Anton-Culver, H., Zanetti, R., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji312 · Cited by 213
Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression
Knudsen, E. S., Buckmaster, C., Chen, T.-T., Feramisco, J. R., & Wang, J. Y. J. (1998) · Genes & Development · doi:10.1101/gad.12.15.2278 · Cited by 210
Self-citationFranco, J., Witkiewicz, A. K., & Knudsen, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2270 · Cited by 207
Self-citationYoung, R. J., Waldeck, K., Martin, C., Foo, J. H., Cameron, D. P., Kirby, L., Do, H., Mitchell, C., Cullinane, C., Liu, W., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12228 · Cited by 206
Franco, J., Balaji, U., Freinkman, E., Witkiewicz, A. K., & Knudsen, E. S. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.094 · Cited by 199
Self-citationTherapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., Genesca, L., Trimarchi, T., Kelliher, M. A., Clark, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.016 · Cited by 183
p16Ink4a in Melanocyte Senescence and Differentiation
Sviderskaya, E. V. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.6.446 · Cited by 179
An integrated view of cyclin E function and regulation
Siu, K. T., Rosner, M. R., & Minella, A. C. (2012) · Cell Cycle · doi:10.4161/cc.11.1.18775 · Cited by 169
Barton, K. L., Misuraca, K., Cordero, F., Dobrikova, E., Min, H. D., Gromeier, M., Kirsch, D. G., & Becher, O. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077639 · Cited by 162
Wardell, S. E., Ellis, M. J., Alley, H. M., Eisele, K. J., VanArsdale, T. L., Dann, S. G., Arndt, K. T., Primeau, T. M., Griffin, E., Shao, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0360 · Cited by 160
Caldon, C. E., Sergio, C. M., Kang, J., Muthukaruppan, A., Boersma, M. N., Stone, A. M., Barraclough, J., Lee, C. S., Black, M. A., Miller, L. D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0963 · Cited by 159
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Perna, D., Karreth, F. A., Rust, A. G., Pérez-Mancera, P. A., Rashid, M., Iorio, F., Alifrangis, C., Arends, M. J., Bosenberg, M., Bollag, G. E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418163112 · Cited by 155
Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153
Marzec, M., Kasprzycka, M., Lai, R. L., Gladden, A. B., Wlodarski, P. K., Tomczak, E. Z., Nowell̀, P. C., DePrimo, S. E., Sadis, S., Eck, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016634 · Cited by 149
Kovatcheva, M., Liu, D. D., Dickson, M. A., Klein, M. E., O’Connor, R., Wilder, F. O., Socci, N. D., Tap, W. D., Schwartz, G. K., Singer, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3364 · Cited by 142
Liu, F., & Korc, M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0562 · Cited by 136
Rivadeneira, D. B., Mayhew, C. N., Thangavel, C., Sotillo, E., Reed, C. A., Graña, X., & Knudsen, E. S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.007 · Cited by 136
Self-citationWang, L., Wang, J., Blaser, B. W., Duchemin, A.-M., Kusewitt, D. F., Liu, T., Caligiuri, M. A., & Briesewitz, R. (2007) · Blood · doi:10.1182/blood-2007-02-071266 · Cited by 134
Finn, R., Crown, J. P., Láng, I., Boér, K., Bondarenko, I., Kulyk, S. V., Ettl, J., Patel, R., Pintér, T., Schmidt, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-s1-6 · Cited by 128
Kalish, L. H., Kwong, R. A., Cole, I. E., Gallagher, R. M., Sutherland, R. L., & Musgrove, E. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0012 · Cited by 127
Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123
Markey, M. P., Angus, S. P., Strobeck, M. W., Williams, S., Gunawardena, R. W., Aronow, B. J., & Knudsen, E. S. (2002) · PubMed · Cited by 123
Self-citationHashizume, R., Zhang, A., Mueller, S., Prados, M. D., Lulla, R. R., Goldman, S., Saratsis, A. M., Mazar, A. P., Stegh, A. H., Cheng, S., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now106 · Cited by 123
CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma
McNeal, A. S., Liu, K., Nakhate, V., Natale, C. A., Duperret, E. K., Capell, B. C., Dentchev, T., Berger, S. L., Herlyn, M., Seykora, J. T., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0196 · Cited by 122
Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.24 · Cited by 121
Self-citationHeilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2923 · Cited by 119
Targeting cell cycle and hormone receptor pathways in cancer
Comstock, C. E. S., Augello, M. A., Goodwin, J. F., de Leeuw, R., Schiewer, M. J., Ostrander, W. F., Burkhart, R. A., McClendon, A. K., McCue, P. A., Trabulsi, E. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.83 · Cited by 119
Aagaard, L., Lukas, J., Bártková, J., Kjerulff, A. A., Strauss, M., & Bártek, J. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610120 · Cited by 115
Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0387 · Cited by 114
Kennedy, A. L., Vallurupalli, M., Chen, L., Crompton, B. D., Cowley, G. S., Vázquez, F., Weir, B. A., Tsherniak, A., Parasuraman, S., Kim, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4903 · Cited by 108
A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model
Menu, E., García, J., Huang, X., Liberto, M. D., Toogood, P. L., Chen, I., Vanderkerken, K., & Chen‐Kiang, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6404 · Cited by 108
Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt
Zhang, J., Xu, K. L., Liu, P., Geng, Y., Wang, B., Gan, W., Guo, J., Wu, F., Chin, Y. R., Berrios, C. J., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.04.023 · Cited by 108
Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Ziemke, E. K., Dosch, J. S., Maust, J. D., Shettigar, A., Sen, A., Welling, T. H., Hardiman, K. M., & Sebolt, J. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0829 · Cited by 102
Logan, J. E., Mostofizadeh, N., Desai, A. J., von Euw, E., Conklin, D. F., Konkankit, V., Hamidi, H., Eckardt, M. A., Anderson, L. A., Chen, H., et al. (2013) · PubMed · Cited by 101
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Turner, N. C., Bartlett, C. H., & Cristofanilli, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1510345 · Cited by 101
Tang, L. H., Contractor, T., Clausen, R., Klimstra, D. S., Du, Y. N., Allen, P. J., Brennan, M. F., Levine, A. J., & Harris, C. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3264 · Cited by 99
Proliferation: the Most Prominent Predictor of Clinical Outcome in Breast Cancer
Desmedt, C., & Sotiriou, C. P. (2006) · Cell Cycle · doi:10.4161/cc.5.19.3254 · Cited by 97
Saab, R. H., Bills, J. L., Miceli, A. P., Anderson, C., Khoury, J. D., Fry, D. W., Navid, F., Houghton, P. J., & Skapek, S. X. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0383 · Cited by 96
Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2021) · Genes & Cancer · doi:10.18632/genesandcancer.211 · Cited by 93
Self-citationSumi, N. J., Kuenzi, B. M., Knezevic, C. E., Rix, L. L. R., & Rix, U. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00368 · Cited by 93
Tao, Z., Blanc, J. M. L., Wang, C., Zhan, T., Zhuang, H., Wang, P., Yuan, Z., & Lü, B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0589 · Cited by 89
CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1
Sathe, A., Koshy, N. R., Schmid, S. C., Thalgott, M. K., Schwarzenböck, S. M., Krause, B. J., Holm, P. S., Gschwend, J. E., Retz, M. M., & Nawroth, R. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.08.082 · Cited by 81
p16INK4a‐induced senescence is disabled by melanoma‐associated mutations
Haferkamp, S., Becker, T. M., Scurr, L. L., Kefford, R. F., & Rizos, H. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00422.x · Cited by 78
Restoration of retinoblastoma mediated signaling to Cdk2 results in cell cycle arrest
Strobeck, M. W., Fribourg, A. F., Puga, A., & Knudsen, E. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203510 · Cited by 78
Self-citationChemical inhibitors of cyclin-dependent kinases
Meijer, L. (1995) · Springer eBooks · doi:10.1007/978-1-4615-1809-9_29 · Cited by 74
Whiteway, S. L., Harris, P. S., Venkataraman, S., Alimova, I. N., Birks, D. K., Donson, A. M., Foreman, N. K., & Vibhakar, R. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1000-7 · Cited by 73
Bhatt, K., Hu, R., Spofford, L. S., & Aplin, A. E. (2006) · Oncogene · doi:10.1038/sj.onc.1209861 · Cited by 70
Knudsen, K. E., Weber, E., Arden, K. C., Cavenee, W. K., Feramisco, J. R., & Knudsen, E. S. (1999) · Oncogene · doi:10.1038/sj.onc.1202910 · Cited by 67
Self-citationTort, F., Bártková, J., Sehested, M., Orntoft, T. F., Lukas, J., & Bártek, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2178 · Cited by 66
Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA
Pérez, M., Muñoz-Galván, S., Jiménez-García, M. P., Marín, J., & Carnero, A. (2015) · Oncotarget · doi:10.18632/oncotarget.5829 · Cited by 63
Butt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-78818-0_12 · Cited by 59
Ismail, A., Bandla, S., Réveiller, M., Toia, L. M., Zhou, Z., Gooding, W. E., Kalatskaya, I., Stein, L. D., D’Souza, M., Litle, V. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0244 · Cited by 54
EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Beck, T. N., Georgopoulos, R., Shagisultanova, E. I., Sarcu, D., Handorf, E. A., Dubyk, C. W., Lango, M. N., Ridge, J. A., Astsaturov, I. A., Serebriiskii, I. G., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0243 · Cited by 54
Musgrove, E. A., Hui, R., Sweeney, K. J. E., Watts, C. K. W., & Sutherland, R. L. (1996) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/bf02013639 · Cited by 53
Bigoni, R., Negrini, M., Veronese, M. L., et al. (1996) · PubMed · Cited by 50
The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes
Paternot, S., Bianca, C., Bisteau, X., & Roger, P. P. (2014) · Cell Cycle · doi:10.4161/15384101.2014.946841 · Cited by 45
Katsumi, Y., Iehara, T., Miyachi, M., Yagyu, S., Tsubai-Shimizu, S., Kikuchi, K., Tamura, S., Kuwahara, Y., Tsuchiya, K., Kuroda, H., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.08.047 · Cited by 42
Vlenterie, M., Hillebrandt-Roeffen, M. H. S., Schaars, E. W. M., Flucke, U. E., Fleuren, E. D. G., Navis, A. C., Leenders, W. P. J., Versleijen‐Jonkers, Y. M. H., & van der Graaf, W. T. A. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5341-x · Cited by 38
Knudsen, E. S., & Witkiewicz, A. K. (2016) · Oncotarget · doi:10.18632/oncotarget.11588 · Cited by 30
Self-citationNemoto, A., Saida, S., Kato, I., Kikuchi, J., Furukawa, Y., Maeda, Y., Akahane, K., Oshiro, H., Goi, K., Kagami, K., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1065 · Cited by 28
Witkiewicz, A. K., Cox, D. W., Rivadeneira, D. E., Ertel, A., Fortina, P. M., Schwartz, G. F., & Knudsen, E. S. (2013) · Oncogene · doi:10.1038/onc.2013.367 · Cited by 26
Self-citationRegulation of CYL /Cyclin D Genes by Colony‐Stimulating Factor 1
Sherr, C. J., Matsushime, H., & Roussel, M. F. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514320.ch13 · Cited by 24
CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation.
Huang, S., Ye, H., Guo, W., et al. (2015) · PubMed · Cited by 22
p27kip1 Protein Levels Reflect a Nexus of Oncogenic Signaling during Cell Transformation
Miller, J. P., Yeh, N., Hofstetter, C. P., Keskin, D., Goldstein, A. S., & Koff, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.361972 · Cited by 9
Cited by
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 393
Targeting CDK2 in cancer: challenges and opportunities for therapy
Tadesse, S., Anshabo, A. T., Portman, N., Lim, E., Tilley, W., Caldon, C. E., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.001 · Cited by 333
CDK4/6 inhibition in breast cancer: current practice and future directions
Pernas, S., Tolaney, S. M., Winer, E. P., & Goel, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786451 · Cited by 316
RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Stalnecker, C. A., & Der, C. J. (2020) · Science Signaling · doi:10.1126/scisignal.aay6013 · Cited by 90
Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
Coffman, L. G., Orellana, T. J., Liu, T., Frisbie, L. G., Normolle, D., Griffith, K., Uppal, S., McLean, K., Berger, J., Boisen, M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160573 · Cited by 17
Metadata
- Authors
- Knudsen, E. S., & Witkiewicz, A. K.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 3
- Issue
- 1
- Pages
- 39-55
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W2568050301
- Cited by
- 285
- References
- 147
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.